Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.
| Autor: | Rodriguez Garzotto A; Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Cortijo Casacajares S; Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Pernaut C; Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Ruiz Ares GJ; Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Otero Blas I; 1Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Heine O; Zentralklinikum Suhl, Suhl, Germany., Turner M; Sandoz International GmbH, Holzkirchen, Germany., Rebollo Laserna F; Sandoz Farmaceutica SA, Madrid, Spain., Cortes Funes H; Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain., Lorenz A; Frauenarztpraxis, Hildburghausen, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of blood medicine [J Blood Med] 2014 Apr 28; Vol. 5, pp. 43-8. Date of Electronic Publication: 2014 Apr 28 (Print Publication: 2014). |
| DOI: | 10.2147/JBM.S57887 |
| Abstrakt: | Background: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia. Methods: Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA. Results: Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups. Conclusion: These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit(®)) for the treatment of cancer patients with chemotherapy-induced anemia. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|